These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 28038704)
1. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors. Yang Y; Lu S; Zeng W; Xie S; Xiao S Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704 [TBL] [Abstract][Full Text] [Related]
2. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors. Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746 [TBL] [Abstract][Full Text] [Related]
4. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens. Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624 [TBL] [Abstract][Full Text] [Related]
5. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin. Wendroth SM; Mentrikoski MJ; Wick MR Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392 [TBL] [Abstract][Full Text] [Related]
6. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249 [TBL] [Abstract][Full Text] [Related]
7. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens. Braxton DR; Cohen C; Siddiqui MT Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285 [TBL] [Abstract][Full Text] [Related]
9. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. Lew M; Pang JC; Jing X; Fields KL; Roh MH Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236 [TBL] [Abstract][Full Text] [Related]
10. GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15. Zhao M; Zhou L; Sun L; Song Y; Guo Y; Zhang X; Zhao F; Wang P; Yue J; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D Diagn Pathol; 2017 Jul; 12(1):51. PubMed ID: 28693610 [TBL] [Abstract][Full Text] [Related]
11. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Shield PW; Papadimos DJ; Walsh MD Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220 [TBL] [Abstract][Full Text] [Related]
12. Markers of metastatic carcinoma of breast origin. Gown AM; Fulton RS; Kandalaft PL Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. Liu H; Shi J; Prichard JW; Gong Y; Lin F Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735 [TBL] [Abstract][Full Text] [Related]
14. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups. Ni YB; Tsang JY; Chan SK; Tse GM Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335 [TBL] [Abstract][Full Text] [Related]
15. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642 [TBL] [Abstract][Full Text] [Related]
16. TRPS1 is a promising marker for all subtypes of breast cancer. Lui JW; Tsang JY; Li J; Ko CW; Tam F; Loong TC; Tse GM Histopathology; 2024 Apr; 84(5):822-836. PubMed ID: 38173281 [TBL] [Abstract][Full Text] [Related]
17. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung. Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644 [TBL] [Abstract][Full Text] [Related]
19. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880 [TBL] [Abstract][Full Text] [Related]
20. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression. Hafez NH; Shaaban HM Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]